Development of Search Strategy for Peptide Inhibitors of Immune Checkpoints

被引:0
作者
S. V. Podlesnykh
D. V. Shanshin
E. A. Kolosova
D. E. Murashkin
O. N. Shaprova
D. N. Shcherbakov
A. I. Chapoval
机构
[1] Altai State University,Russian
[2] ”VECTOR” State Research Center of Virology and Biotechnology,American Anti
[3] Arizona State University,Cancer Center
来源
Russian Journal of Bioorganic Chemistry | 2018年 / 44卷
关键词
synthetic peptides; co-stimulatory molecules; immune checkpoints; immune response; peptide microchips; immunotherapy; immunomodulation; phage display;
D O I
暂无
中图分类号
学科分类号
摘要
Current strategy for the blockade of molecules inhibiting T-cell immunity, the immune checkpoints (ICP), such as CTLA-4, PD-1, and B7-H1(PD-L1), using monoclonal antibodies (mAbs), showed significant clinical effects in cancer immunotherapy. In this kind of therapy, antibodies do not kill tumor cells directly, but block inhibitory signals for T lymphocytes, resulting in activation of the immune response cascade that eliminate malignant cells and lead to tumor degradation. However, the mAb preparations have some limitations, and the development of new low-molecular-weight antagonists (for example, peptides) is an important issue. In this study, we used peptide microarrays and phage display libraries to search for peptides that interact with the immune checkpoints. We found peptides that specifically bind CTLA-4, PD-1, B7-1, B7-2 and B7-H1(PD-L1) which play important role in the regulation of the immune responses. These synthetic peptides can be applied to the development of new immunomodulating drugs for cancer immunotherapy.
引用
收藏
页码:150 / 157
页数:7
相关论文
共 106 条
  • [1] Abelev G.I.(1996)undefined Soros. Obrazovat. Zh. 5 4-10
  • [2] Grosso F.J.(2013)undefined Cancer Immun. 13 5-14
  • [3] Jure-Kunkel M.N.(2016)undefined Am. J. Clin. Oncol. 39 98-106
  • [4] Buchbinder E.I.(2015)undefined J. Clin. Oncol. 33 1974-1982
  • [5] Desai A.(2012)undefined Nat. Rev. Cancer 12 252-264
  • [6] Postow M.A.(2015)undefined Science 348 56-61
  • [7] Callahan M.K.(2005)undefined Med. Immunol. 7 347-354
  • [8] Wolchok J.D.(2002)undefined Immunol. Lett. 84 179-183
  • [9] Pardoll D.M.(2003)undefined Immunol. Rev. 192 143-160
  • [10] Sharma P.(2016)undefined Pharmacotherapy 36 317-334